Longeveron Inc - Ordinary Shares - Class A
NASDAQ:LGVN 4:00:00 PM EDT
| Market Cap (Intraday) | 13.21M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.13 |
| 50-Day MA | $2.72 |
| 200-Day MA | $5.62 |
Longeveron Inc - Ordinary Shares - Class A Stock, NASDAQ:LGVN
Life Science & Technology Park, 1951 Northwest 7th Avenue, Miami, Florida 33136
United States of America
Phone: +1.305.909.0840
Number of Employees: 25
Description
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.